Company Profile
Apellis Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- APLS
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Apellis Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
41.03 USD (-0.07%)
Close
Last updated: May 13, 2026 at 00:00
5.25B USD
Market cap
Why the stock is moving
APLS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Apellis Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Apellis Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Apellis Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Apellis Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
Source: Apellis Pharmaceuticals
- 02
- 03
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Source: Apellis Pharmaceuticals
- 04
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Source: Apellis Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Apellis Pharmaceuticals (APLS)?
Apellis Pharmaceuticals (APLS) most recently closed at 41.03 USD, a -0.07% move versus the previous session.
What is the market cap of Apellis Pharmaceuticals (APLS)?
Apellis Pharmaceuticals currently has a market capitalization of 5.25B USD on BioPharmSignal.
What does Apellis Pharmaceuticals do?
Apellis Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is APLS stock listed?
Apellis Pharmaceuticals (APLS) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Apellis Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Apellis?
Apellis Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Apellis Pharmaceuticals targeting with Apellis?
Apellis Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Pharmaceuticals?
Apellis Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.